{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"Due to the lack of a clear signal of robust clinical activity during Phase 1, the study was terminated early and Phase 2 was not initiated. Dose-limiting toxicity and recommended Phase 2 dose determination were not performed."},"pointOfContact":{"email":"info@adaptimmune.com","organization":"Adaptimmune Ltd","phone":"+44 (0)1235 430000","title":"Adaptimmune Ltd"}}